Gumintad, Mark P.
HRN: 27-48-78 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/14/2025
CEFTRIAXONE 1G (VIAL)
07/14/2025
07/21/2025
IVTT
2g
OD
Infected Wound With Abscess
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes